We assess the impact of introduction of sildenafil on alprostadil injection and penile implant surgery for the treatment of erectile dysfunction (ED) at our institution and in Taiwan. The data of national sales of sildenafil, alprostadil injection and penile implant were provided by industry companies. In the meanwhile, we analyzed the users of the above-mentioned three treatments at our institution. The national sales of sildenafil grew 136% from 0.8 million tablets in 1999 to 1.6 million tablets in 2002, while those of alprostadil injection dropped 33% after the marketing of sildenafil and of penile implant dropped 40% after the marketing of alprostadil injection and sildenafil. The market share of drugstores for sildenafil rose from 41% in 1999 to 72% in 2002. The trend of sales of sildenafil at our institution was similar to that of national sales from hospitals. Mean age of the sildenafil new users was becoming younger in the past 4 y (P<0.001). Of the new users of alprostadil injection and the recipients of penile implant, the commonest age group shifted from the range of 60–69 y before the launch of sildenafil to that of over 70 y after (P<0.05). In conclusion, the introduction of sildenafil has prompted more men as well as younger men with ED to seek treatment. Part of the roles of alprostadil injection and penile implants in this field are substituted by sildenafil and the commonest age group of their users becomes older than before.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Krane RJ . Changes in ED therapy in the Viagra era. World J Urol 2001; 19: 23–24.
Carson CC et al. The efficacy of sildenafil citrate (Viagra®) in clinical populations: an update. Urology 2002; 60 (Suppl 2): 12–27.
Padma-Nathan H et al. A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002; 60 (Suppl 2): 67–90.
Wysowski DK, Swann J . Use of medications for erectile dysfunction in the United States, 1996 through 2001. J Urol 2003; 169: 1040–1042.
Wilson EC et al. The cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions. Pharmacoeconomics 2002; 20: 879–889.
Montorsi F et al. Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E(1) intracavernosal injection therapy to oral sildenafil citrate. Int J Impot Res 2003; 15: 444–449.
Jarow JP, Burnett AL, Geringer AM . Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722–725.
Jiann BP et al. What we learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical practice. Int J Impot Res 2003; 15: 412–417.
Seftel AD . Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. J Urol 2003; 169: 1999–2007.
Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151: 54–61.
Rights and permissions
About this article
Cite this article
Jiann, BP., Yu, CC. & Su, CC. Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sales. Int J Impot Res 16, 527–530 (2004). https://doi.org/10.1038/sj.ijir.3901259
- penile implant
- erectile dysfunction
This article is cited by
Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors
International Journal of Impotence Research (2014)
Compliance of sildenafil treatment for erectile dysfunction and factors affecting it
International Journal of Impotence Research (2006)